About Karyopharm Therapeutics (NASDAQ:KPTI)
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600
Debt
Debt-to-Equity RatioN/A
Current Ratio3.00%
Quick Ratio3.00%
Price-To-Earnings
Trailing P/E Ratio-5.00
Forward P/E Ratio-5.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.61 million
Price / Sales433.28
Cash FlowN/A
Price / CashN/A
Book Value$2.61 per share
Price / Book5.38
Profitability
EPS (Most Recent Fiscal Year)($2.81)
Net Income$-128,980,000.00
Net MarginsN/A
Return on Equity-89.62%
Return on Assets-75.29%
Miscellaneous
Employees154
Outstanding Shares49,650,000
Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions
What is Karyopharm Therapeutics' stock symbol?
Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."
How were Karyopharm Therapeutics' earnings last quarter?
Karyopharm Therapeutics (NASDAQ:KPTI) released its earnings results on Thursday, March, 15th. The company reported ($0.80) EPS for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.14. The firm earned $1.53 million during the quarter, compared to the consensus estimate of $2.26 million. Karyopharm Therapeutics's revenue for the quarter was up 3163.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.65) EPS. View Karyopharm Therapeutics' Earnings History.
When is Karyopharm Therapeutics' next earnings date?
What price target have analysts set for KPTI?
8 brokers have issued twelve-month price targets for Karyopharm Therapeutics' stock. Their forecasts range from $18.00 to $26.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $21.00 in the next year. View Analyst Ratings for Karyopharm Therapeutics.
What are Wall Street analysts saying about Karyopharm Therapeutics stock?
Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
- 1. Canaccord Genuity analysts commented, "We had the pleasure of hosting Karyopharm CEO Michael Kauffman and CFO Mike Falvey for meetings with institutional investors in New York City. Overall, investors focused on upcoming and potentially registration-supporting datasets for lead drug candidate selinexor in two trials: STORM in penta-refractory multiple myeloma (April 30) and SADAL in relapsed/refractory diffuse large B-cell lymphoma (DLBCL, 2H). We came away with increased confidence that Accelerated Approval is a viable path for selinexor, continue to view the available data as indicative of benefit, and reiterate our BUY rating and $22 PT." (4/10/2018)
- 2. Cantor Fitzgerald analysts commented, "STORM Data. Top-line data from the STORM (Phase IIb) trial in penta- refractory multiple myeloma, which has been granted accelerated approval, are expected in late-April." (3/21/2018)
- 3. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (3/21/2018)
Who are some of Karyopharm Therapeutics' key competitors?
Some companies that are related to Karyopharm Therapeutics include Zogenix (ZGNX), Prothena (PRTA), ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Revance Therapeutics (RVNC) and Dynavax Technologies (DVAX).
Who are Karyopharm Therapeutics' key executives?
Karyopharm Therapeutics' management team includes the folowing people:
- Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 55)
- Dr. Sharon Shacham, Co-Founder, Co-Chairman of Scientific Advisory Board, Pres & Chief Scientific Officer (Age 48)
- Dr. Mansoor Raza Mirza, Clinical Consultant, Director and Member of Scientific Advisory Board (Age 57)
- Mr. Michael F. Falvey, Exec. VP, CFO & Treasurer (Age 59)
- Mr. Michael J. Todisco, Acting Principal Financial & Accounting Officer (Age 53)
Has Karyopharm Therapeutics been receiving favorable news coverage?
Headlines about KPTI stock have trended somewhat positive this week, Accern reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Karyopharm Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave media stories about the company an impact score of 46.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Karyopharm Therapeutics?
Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Karyopharm Therapeutics' stock price today?
One share of KPTI stock can currently be purchased for approximately $14.05.
How big of a company is Karyopharm Therapeutics?
Karyopharm Therapeutics has a market capitalization of $724.43 million and generates $1.61 million in revenue each year. The company earns $-128,980,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Karyopharm Therapeutics employs 154 workers across the globe.
How can I contact Karyopharm Therapeutics?
Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]
MarketBeat Community Rating for Karyopharm Therapeutics (KPTI)
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Karyopharm Therapeutics in the last 12 months. Their average twelve-month price target is $21.00, suggesting that the stock has a possible upside of 49.47%. The high price target for KPTI is $26.00 and the low price target for KPTI is $18.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $21.00 | $20.25 | $17.4286 | $16.00 |
| Price Target Upside: | 49.47% upside | 29.31% upside | 65.83% upside | 39.98% upside |
Karyopharm Therapeutics (NASDAQ:KPTI) Consensus Price Target History
Karyopharm Therapeutics (NASDAQ:KPTI) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Karyopharm Therapeutics (NASDAQ:KPTI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Karyopharm Therapeutics (NASDAQ KPTI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.71%
Institutional Ownership Percentage: 62.45%
Karyopharm Therapeutics (NASDAQ KPTI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/18/2018 | Michael Kauffman | CEO | Sell | 10,000 | $14.79 | $147,900.00 | 522,143 |  |
| 4/9/2018 | Sharon Shacham | Insider | Sell | 10,000 | $12.48 | $124,800.00 | 723,510 | |
| 3/19/2018 | Michael Kauffman | CEO | Sell | 10,000 | $15.29 | $152,900.00 | 522,143 | |
| 3/12/2018 | Mansoor Raza Mirza | Director | Sell | 2,500 | $17.01 | $42,525.00 | 2,500 | |
| 3/7/2018 | Sharon Shacham | Insider | Sell | 10,000 | $16.15 | $161,500.00 | 723,510 | |
| 3/5/2018 | Christopher Brett Primiano | EVP | Sell | 2,500 | $16.03 | $40,075.00 | 4,881 | |
| 2/20/2018 | Michael Kauffman | CEO | Sell | 10,000 | $14.79 | $147,900.00 | | |
| 2/16/2018 | Christopher Brett Primiano | EVP | Sell | 2,500 | $15.01 | $37,525.00 | | |
| 2/7/2018 | Christopher Brett Primiano | EVP | Sell | 1,500 | $13.00 | $19,500.00 | 9,881 | |
| 2/7/2018 | Sharon Shacham | Insider | Sell | 10,000 | $12.50 | $125,000.00 | 723,510 | |
| 1/18/2018 | Michael Kauffman | CEO | Sell | 10,000 | $10.09 | $100,900.00 | 522,143 | |
| 1/8/2018 | Sharon Shacham | Insider | Sell | 10,000 | $10.08 | $100,800.00 | 723,510 | |
| 12/18/2017 | Michael Kauffman | CEO | Sell | 10,000 | $9.16 | $91,600.00 | 522,143 | |
| 12/12/2017 | Christopher Brett Primiano | SVP | Sell | 27,042 | $10.28 | $277,991.76 | 11,381 | |
| 12/7/2017 | Sharon Shacham | Insider | Sell | 10,000 | $10.39 | $103,900.00 | | |
| 11/7/2017 | Christopher Brett Primiano | SVP | Sell | 4,958 | $11.25 | $55,777.50 | | |
| 10/2/2017 | Christopher Brett Primiano | SVP | Sell | 1,500 | $12.00 | $18,000.00 | | |
| 10/2/2017 | Mansoor Raza Mirza | Director | Sell | 2,000 | $12.00 | $24,000.00 | | |
| 9/15/2017 | Christopher Brett Primiano | SVP | Sell | 2,000 | $11.00 | $22,000.00 | 12,881 | |
| 9/15/2017 | Mansoor Raza Mirza | Director | Sell | 2,882 | $11.00 | $31,702.00 | 2,882 | |
| 9/11/2017 | Mansoor Raza Mirza | Director | Sell | 118 | $11.00 | $1,298.00 | 118 | |
| 8/29/2017 | Christopher Brett Primiano | SVP | Sell | 2,195 | $10.00 | $21,950.00 | | |
| 6/26/2017 | Christopher Brett Primiano | SVP | Sell | 805 | $10.03 | $8,074.15 | | |
| 11/14/2016 | Ran Frenkel | Insider | Sell | 3,309 | $10.06 | $33,288.54 | 14,691 | |
| 6/23/2016 | Ltd Chione | Major Shareholder | Sell | 18,824 | $8.03 | $151,156.72 | | |
| 6/13/2016 | Ltd Chione | Major Shareholder | Sell | 7,074 | $8.51 | $60,199.74 | 8,568,744 | |
| 6/9/2016 | Ltd Chione | Major Shareholder | Sell | 45,541 | $9.21 | $419,432.61 | 8,605,818 | |
| 6/7/2016 | Ltd Chione | Major Shareholder | Sell | 40,000 | $9.24 | $369,600.00 | 8,641,359 | |
| 6/2/2016 | Ltd Chione | Major Shareholder | Sell | 17,855 | $9.65 | $172,300.75 | 8,661,359 | |
| 6/1/2016 | Ltd Chione | Major Shareholder | Sell | 74,664 | $9.61 | $717,521.04 | 8,713,878 | |
| 5/31/2016 | Ltd Chione | Major Shareholder | Sell | 17,096 | $9.66 | $165,147.36 | 8,713,878 | |
| 5/27/2016 | Ltd Chione | Major Shareholder | Sell | 40,000 | $9.58 | $383,200.00 | 8,713,878 | |
| 5/26/2016 | Ltd Chione | Major Shareholder | Sell | 46,122 | $9.73 | $448,767.06 | 8,772,060 | |
| 5/23/2016 | Ltd Chione | Major Shareholder | Sell | 93,932 | $8.54 | $802,179.28 | 8,873,932 | |
| 5/18/2016 | Ltd Chione | Major Shareholder | Sell | 63,800 | $8.15 | $519,970.00 | 8,923,932 | |
| 5/16/2016 | Ltd Chione | Major Shareholder | Sell | 10,400 | $8.01 | $83,304.00 | 8,967,732 | |
| 5/11/2016 | Ltd Chione | Major Shareholder | Sell | 31,868 | $8.24 | $262,592.32 | 8,980,000 | |
| 12/8/2015 | Mansoor Raza Mirza | Director | Sell | 15,000 | $15.01 | $225,150.00 | | |
| 4/7/2015 | Ran Frenkel | EVP | Buy | 3,000 | $31.81 | $95,430.00 | | |
| 4/2/2015 | Barry E Greene | Director | Buy | 3,000 | $29.31 | $87,930.00 | | |
| 4/2/2015 | Justin A Renz | CFO | Buy | 5,000 | $29.71 | $148,550.00 | | |
| 1/12/2015 | Deepika Pakianathan | Director | Buy | 45,454 | $33.00 | $1,499,982.00 | | |
| 1/12/2015 | Michael Kauffman | CEO | Sell | 50,000 | $33.00 | $1,650,000.00 | | |
| 1/12/2015 | Sharon Shacham | Insider | Sell | 25,000 | $33.00 | $825,000.00 | | |
| 12/2/2014 | Mansoor Raza Mirza | Director | Sell | 10,000 | $43.52 | $435,200.00 | | |
| 12/1/2014 | Ltd Chione | Major Shareholder | Sell | 278,115 | $41.92 | $11,658,580.80 | | |
| 11/25/2014 | Ltd Chione | Major Shareholder | Sell | 242,800 | $42.40 | $10,294,720.00 | | |
| 11/19/2014 | Ltd Chione | Major Shareholder | Sell | 65,968 | $40.09 | $2,644,657.12 | | |
| 11/12/2014 | Ltd Chione | Major Shareholder | Sell | 164,100 | $42.83 | $7,028,403.00 | | |
| 11/11/2014 | Ltd Chione | Major Shareholder | Sell | 54,100 | $42.51 | $2,299,791.00 | | |
| 11/10/2014 | Ltd Chione | Major Shareholder | Sell | 65,000 | $43.40 | $2,821,000.00 | | |
| 11/10/2014 | Mansoor Raza Mirza | Director | Sell | 5,000 | $45.05 | $225,250.00 | | |
| 11/6/2014 | Ltd Chione | Major Shareholder | Sell | 272,784 | $42.11 | $11,486,934.24 | | |
| 10/29/2014 | Mansoor Raza Mirza | Director | Sell | 3,500 | $40.05 | $140,175.00 | | |
| 9/26/2014 | Marcin Czernik | Major Shareholder | Sell | 50,000 | $42.54 | $2,127,000.00 | | |
| 9/24/2014 | Marcin Czernik | Major Shareholder | Sell | 22,498 | $40.32 | $907,119.36 | | |
| 9/18/2014 | Marcin Czernik | Major Shareholder | Sell | 12,347 | $40.24 | $496,843.28 | | |
| 9/17/2014 | Marcin Czernik | Major Shareholder | Sell | 9,569 | $40.26 | $385,247.94 | | |
| 9/12/2014 | Ltd Chione | Major Shareholder | Sell | 4,312 | $41.12 | $177,309.44 | | |
| 9/8/2014 | Marcin Czernik | Major Shareholder | Sell | 35,666 | $39.92 | $1,423,786.72 | | |
| 9/4/2014 | Marcin Czernik | Major Shareholder | Sell | 12,795 | $38.07 | $487,105.65 | | |
| 8/27/2014 | Marcin Czernik | Major Shareholder | Sell | 43,699 | $38.80 | $1,695,521.20 | | |
| 8/25/2014 | Marcin Czernik | Major Shareholder | Sell | 4,389 | $38.08 | $167,133.12 | | |
| 8/15/2014 | Marcin Czernik | Major Shareholder | Sell | 8,027 | $39.11 | $313,935.97 | | |
| 8/11/2014 | Marcin Czernik | Major Shareholder | Sell | 36,979 | $37.30 | $1,379,316.70 | | |
| 7/30/2014 | Marcin Czernik | Major Shareholder | Sell | 21,570 | $36.20 | $780,834.00 | | |
| 7/29/2014 | Ltd Chione | Major Shareholder | Sell | 30,000 | $35.20 | $1,056,000.00 | | |
| 7/23/2014 | Ltd Plio | Insider | Sell | 500,000 | $35.54 | $17,770,000.00 | | |
| 7/2/2014 | Michael Kauffman | CEO | Sell | 200,000 | $42.50 | $8,500,000.00 | | |
| 6/18/2014 | Sharon Shacham | Insider | Sell | 20,000 | $41.76 | $835,200.00 | | |
| 6/17/2014 | Michael Kauffman | CEO | Sell | 20,000 | $41.76 | $835,200.00 | | |
| 5/23/2014 | Deepika Pakianathan | Director | Buy | 114,419 | $26.18 | $2,995,489.42 | | |
| 5/13/2014 | Paul Brannelly | SVP | Buy | 1,000 | $28.06 | $28,060.00 | 64,636 | |
| 11/12/2013 | Deepika Pakianathan | Director | Buy | 312,500 | $16.00 | $5,000,000.00 | | |
(Data available from 1/1/2013 forward)
Karyopharm Therapeutics (NASDAQ KPTI) News Headlines
| Source: |
|
Karyopharm Therapeutics (NASDAQ:KPTI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Karyopharm Therapeutics (NASDAQ:KPTI) Income Statement, Balance Sheet and Cash Flow Statement
Karyopharm Therapeutics (NASDAQ KPTI) Stock Chart for Monday, April, 23, 2018
Loading chart…
